Therapeutic Proteins International Announces Appointment of Peter F. Moesta, Ph.D. as Chief Executive Officer

CHICAGO--(BUSINESS WIRE)--The board of Therapeutic Proteins International (TPI) today announced the appointment of Peter F. Moesta, Ph.D. as its new chief executive officer, effective November 2, 2015. Dr. Moesta will also serve on the company's board.

"I am pleased to welcome Dr. Peter Moesta as our new chief executive officer"
Dr. Moesta has more than 30 years of experience in the biopharmaceutical industry, most recently as the senior vice president for biologics development and operations at Bristol-Myers Squibb. He oversaw the development, production and worldwide launch of important medicines, such as Yervoy and Opdivo. Dr. Moesta led the rapid expansion of development and manufacturing facilities around the world. Previous to this role, he held various leadership positions at Abbott Laboratories and BASF AG. As the vice president for the biologics manufacturing division at Abbott, he led the CMC effort to obtain approval for Humira.

"I am pleased to welcome Dr. Peter Moesta as our new chief executive officer," said Dr. Sarfaraz Niazi, Chairman of TPI. "Peter brings a breadth of knowledge and expertise in biologics development and production to lead the organization, as we prepare to launch new biosimilars in the next few years."

"I share the passion of TPI in providing high quality, affordable alternatives to branded biologics and making a difference in patients' lives," said Dr. Moesta. "I look forward to leading TPI with its team of scientists and engineers, who are recognized for their exceptional capabilities and experience."

Dr. Moesta received his master's degree in chemistry and his doctoral degree in biochemistry from the University of Freiburg in Germany. He completed his postdoctoral fellowships at the University of Freiburg and University of California, Los Angeles.

About TheraProteins International (TPI)

TPI is an innovative, U.S., pure play biosimilar company focused on developing recombinant proteins and antibody products for major regulated markets and strategic markets globally. Our vision is to make biosimilar medications affordable. TPI has utilized its proprietary, single-use technology platform, MayaBio®, to build a strong pipeline of biosimilar candidates. Headquartered in Chicago and led by a team of experienced industry leaders, our patented bioprocessing technology along with our robust in-house characterization and analytical similarity programs allow TPI to operate nimbly in a rapidly evolving global market.

Learn more about biosimilars: http://theraproteins.com/about-biosimilars/

Contacts

TheraProteins International
Andrew Bourgoin, +1-312-953-4323
External Communications
[email protected]

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.